<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The definition of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> is currently under discussion </plain></SENT>
<SENT sid="1" pm="."><plain>It is now suggested that a distal esophagus coated with cylinder epithelium with cardia-fundus mucosa should also be classified as <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> because the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is significantly increased even without histological evidence of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> with goblet cells </plain></SENT>
<SENT sid="2" pm="."><plain>The results of recent epidemiological investigations imply that the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk of cylinder cell <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and low grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> has previously been overestimated </plain></SENT>
<SENT sid="3" pm="."><plain>The histological detection of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> still remains the best biomarker for estimation of the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Exact determination of invasion depth in the mucosa, respective submucosa is now established as prognostic marker for overall survival in Patients with early <z:mp ids='MP_0002038'>carcinomas</z:mp> and this classification is useful for therapy decisions (endoscopic versus surgical removal) </plain></SENT>
<SENT sid="5" pm="."><plain>In advanced Barrett <z:mp ids='MP_0002038'>carcinoma</z:mp> following neoadjuvant therapy the lymph node status (ypN) is a better prognostic factor than the ypT category </plain></SENT>
<SENT sid="6" pm="."><plain>In metastasized <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> therapies targeting HER2/new, EGFR or c-Met have been investigated explicitly in Barrett <z:mp ids='MP_0002038'>carcinoma</z:mp> only in phase I/II studies, whereby the predictive value of appropriate molecular pathology investigations is not yet reliably established </plain></SENT>
</text></document>